These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 17968437)

  • 1. Role of obesity and adiposity in polycystic ovary syndrome.
    Diamanti-Kandarakis E
    Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S8-13; discussion S31-2. PubMed ID: 17968437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abdominal adiposity and the polycystic ovary syndrome.
    Escobar-Morreale HF; San Millán JL
    Trends Endocrinol Metab; 2007 Sep; 18(7):266-72. PubMed ID: 17693095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome.
    Moran L; Norman RJ
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):719-36. PubMed ID: 15380143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome and type 2 diabetes mellitus.
    De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
    Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term risks of polycystic ovaries syndrome].
    Lefebvre P; Raingeard I; Renard E; Bringer J
    Gynecol Obstet Fertil; 2004 Mar; 32(3):193-8. PubMed ID: 15123116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lifestyle modification in the management of polycystic ovary syndrome.
    Hoeger KM
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):293-310. PubMed ID: 16772159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.
    Moran L; Teede H
    Hum Reprod Update; 2009; 15(4):477-88. PubMed ID: 19279045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and polycystic ovary syndrome.
    Barber TM; McCarthy MI; Wass JA; Franks S
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):137-45. PubMed ID: 16886951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
    Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
    Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk in women with polycystic ovary syndrome.
    Giallauria F; Orio F; Palomba S; Lombardi G; Colao A; Vigorito C
    J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):987-92. PubMed ID: 18799960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
    Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
    Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian function and obesity--interrelationship, impact on women's reproductive lifespan and treatment options.
    Rachoń D; Teede H
    Mol Cell Endocrinol; 2010 Mar; 316(2):172-9. PubMed ID: 19818376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of weight and distribution of adipose tissue in functional hyperandrogenism].
    Pasquali R; Vicennati V; Gambineri A
    Contracept Fertil Sex; 1998 May; 26(5):372-5. PubMed ID: 9648381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.